Non–Small Cell Lung Cancer, Version 6.2015

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Camidge, D. R., Bang, Y., Kwak, E. L., Iafrate, A. J., Varella‐Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. I., Kim, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,267

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897

Management of non-small-cell lung cancer: recent developments

Reck, M., Heigener, D. F., Mok, T. S. K., Soria, J., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 730

Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population

Rodig, S. J., Mino-Kenudson, M. A., Đačić, S., Yeap, B. Y., Shaw, A. T., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N. I., Mark, E. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 677

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers

Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 598

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Li, T., Kung, H., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 522

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

Drilon, A. E. D. C., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P. J., Ross, J. S., Miller, V. A., Ginsberg, M. S., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 467

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70355-3 · Cited by 425

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Mino-Kenudson, M. A., Chirieac, L. R., Law, K., Hornick, J. L., Lindeman, N. I., Mark, E. J., Cohen, D., Johnson, B. E., Janne, P. A., Iafrate, A. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2845 · Cited by 424

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Dias-Santagata, D. C., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J. E., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 393

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlési, F., Filleron, T., Dingemans, A. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 370

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 363

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 358

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Camidge, D. R., Kono, S. A., Flacco, A., Tan, A. C., Doebele, R. C., Zhou, Q. H., Crinò, L., Franklin, W. A., & Varella‐Garcia, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0851 · Cited by 341

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 306

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304

Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

D’Angelo, S. P., Pietanza, M. C., Johnson, M. L., Riely, G. J., Miller, V. A., Sima, C. S., Zakowski, M. F., Rusch, V. W., Ladanyi, M., & Kris, M. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6181 · Cited by 302

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 302

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

Leighl, N. B., Rekhtman, N., Biermann, W. A., Huang, J., Mino-Kenudson, M., Ramalingam, S. S., West, H., Whitlock, S., & Somerfield, M. R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3055 · Cited by 281

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 250

Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

Han, S., Kim, T., Jeon, Y. K., Hwang, P. G., Im, S., Lee, K.-H., Kim, J. H., Kim, D., Heo, D. S., Kim, N. K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2845 · Cited by 250

KRAS Mutation: Should We Test for It, and Does It Matter?

Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 233

Clinical next‐generation sequencing in patients with non–small cell lung cancer

Hagemann, I. S., Devarakonda, S. H. K., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., et al. (2014) · Cancer · doi:10.1002/cncr.29089 · Cited by 232

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W. J., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230

Recent Clinical Advances in Lung Cancer Management

Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 222

Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

Pao, W. J., & Ladanyi, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1387 · Cited by 214

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

Thunnissen, E., Bubendorf, L., Dietel, M., Elmberger, G., Kerr, K. M., López‐Ríos, F., Moch, H., Olszewski, W. T., Pauwels, P., Penault-Llorca, F. M., et al. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1281-4 · Cited by 212

EGFR testing in lung cancer is ready for prime time

Hirsch, F. R., & Bunn, P. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70110-x · Cited by 200

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators

Wynes, M. W., Sholl, L. M., Dietel, M., Schuuring, E. M. D., Tsao, M., Yatabe, Y., Tubbs, R. R., & Hirsch, F. R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000115 · Cited by 165

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression

Kim, H., Yoo, S.-B., Choe, J., Paik, J. H., Xu, X., Nitta, H., Zhang, W., Grogan, T. M., Lee, C., Jheon, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821cfc73 · Cited by 162

Computed Tomography Screening for Lung Cancer: Has It Finally Arrived? Implications of the National Lung Screening Trial

Aberle, D. R., Abtin, F. G., & Brown, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3110 · Cited by 159

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

Gazdar, A. F., Robinson, L. D., Oliver, D., Xing, C., Travis, W. D., Soh, J., Toyooka, S., Watumull, L. M., Xie, Y., Kernstine, K. H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000130 · Cited by 156

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 142

Lung Cancer Screening, Version 1.2015

Wood, D. E., Kazerooni, E. A., Baum, S. L., Dransfield, M. T., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D. M., Klippenstein, D. L., Kumar, R., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0006 · Cited by 138

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 130

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the L ung C ancer M utation C onsortium

Villaruz, L. C., Socinski, M. A., Abberbock, S. R., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2014) · Cancer · doi:10.1002/cncr.29042 · Cited by 127

Targeted therapy for non-small-cell lung cancer: past, present and future

Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 123

Crizotinib and Testing for ALK

Shaw, A. T., Solomon, B. J., & Kenudson, M. M. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0115 · Cited by 123

ALK Status Testing in Non–Small Cell Lung Carcinoma

Minca, E. C., Portier, B. P., Wang, Z., Lanigan, C. P., Farver, C. F., Feng, Y., Ma, P. C., Arrossi, V., Pennell, N. A., & Tubbs, R. R. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.01.004 · Cited by 121

EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116

The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

Atherly, A. J., & Camidge, D. R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.60 · Cited by 104

Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma

Peters, S., Michielin, O. A., & Zimmermann, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6143 · Cited by 104

ALK Rearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

Alì, G., Proietti, A., Pelliccioni, S., Niccoli, C., Lupi, C., Sensi, E., Giannini, R., Borrelli, N., Menghi, M., Chella, A., et al. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0388-oa · Cited by 86

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer

Weickhardt, A. J., Aisner, D. L., Franklin, W. A., Varella‐Garcia, M., Doebele, R. C., & Camidge, D. R. (2012) · Cancer · doi:10.1002/cncr.27913 · Cited by 85

Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort

Yu, H. A., Arcila, M. E., Fleischut, M. H., Stadler, Z. K., Ladanyi, M., Berger, M. F., Robson, M. E., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000052 · Cited by 82

Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria

von Laffert, M., Warth, A., Penzel, R., Schirmacher, P., Kerr, K. M., Elmberger, G., Schildhaus, H., Büttner, R., López‐Ríos, F., Reu, S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000332 · Cited by 76

NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.

Ettinger, D. S., Cox, J. D., Ginsberg, R. J., Komaki, R. U., Kris, M. G., Livingston, R. B., & Sugarbaker, D. J. (1996) · PubMed · Cited by 71

Ten Years of Progress in Non–Small Cell Lung Cancer

Ettinger, D. S. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0029 · Cited by 63

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

Lund‐Iversen, M., Kleinberg, L., Fjellbirkeland, L., Helland, Å., & Brustugun, O. T. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182614a9d · Cited by 62

EGFR Assays in Lung Cancer

Đačić, S. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817bf5a9 · Cited by 53

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

Zhou, J., Zhao, J., Sun, K., Wang, B., Wang, L., Chen, X., Zheng, J., You, Q., Wang, X., Ding, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092828 · Cited by 48

Identification of driver mutations in lung cancer: first step in personalized cancer

Planchard, D. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0263-z · Cited by 38

Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma

Shepherd, F. A., & Tsao, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3996 · Cited by 28

The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence

Weickhardt, A. J., & Camidge, D. R. (2011) · Clinical Investigation · doi:10.4155/cli.11.92 · Cited by 22

Molecular profiling of lung cancer

Minárik, M. (2016) · Onkologie · doi:10.36290/xon.2016.003 · Cited by 16

How to judge the cancer services benefit component of your health insurance plan

Mortenson, L. E. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 10

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

Chun, S. G., Hu, C., Choy, H., Komaki, R. U., Timmerman, R. D., Schild, S. E., Bogart, J. A., Dobelbower, M. C., Bosch, W. R., Galvin, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1378 · Cited by 747

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Cheng, T. D., Cramb, S. M., Baade, P. D., Youlden, D. R., Nwogu, C. E., & Reid, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.021 · Cited by 613

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 593

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery

Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z. X., Welsh, J. W., Lin, S. H., O’Reilly, M. S., Jeter, M. D., Balter, P. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00401-0 · Cited by 322

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

Reckamp, K. L. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0046 · Cited by 28

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Aisner, D. L., & Riely, G. J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.5020 · Cited by 39

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

Vigneswaran, J., Tan, Y. C., Murgu, S. D., Won, B. M., Patton, K. A., Villaflor, V. M., Hoffman, P. C., Hensing, T. A., Hogarth, D. K., Malik, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7739 · Cited by 27

How and when to use genetic markers for nonsmall cell lung cancer

Lazarus, D. R., & Ost, D. E. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328362075c · Cited by 17

Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer

Mino-Kenudson, M. A., & Mark, E. J. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2011-0029-rai.1 · Cited by 33